Cargando…
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical in...
Autores principales: | Moreno-Torres, Marta, Quintás, Guillermo, Castell, José V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227129/ https://www.ncbi.nlm.nih.gov/pubmed/35736496 http://dx.doi.org/10.3390/metabo12060564 |
Ejemplares similares
-
Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021) -
The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics
por: Quintás, Guillermo, et al.
Publicado: (2023) -
Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved
por: Martínez-Sena, Teresa, et al.
Publicado: (2023) -
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021) -
Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)